Introduction
============

Rosaprostol (**1**) is a trade name for 7-(2-hexyl-5-hydroxycyclopentane)heptanoic acid ([Fig. 1](#F1){ref-type="fig"}) which belongs to a series of 19,20-dinorprostanoic acid derivatives. It exhibits gastric antisecretory activity and cytoprotective action without the undesired side effects common to other prostanoids like diarrhea, hypotension and uterine stimulation \[[@R1]--[@R8]\]. The sodium salt of **1** as a 1:1 mixture of the racemic 1,2-*trans*-1,5-*cis* and 1,2-*trans*-1,5-*trans* diastereoisomers has been marketed in Italy as Rosal for the treatment of gastric and duodenal ulcers \[[@R9]\]. Because of the therapeutical importance, the synthesis of rosaprostol (**1**) has been attempted by many research groups in academia and industry. These include a patented synthesis of **1** starting from ricinoleic acid \[[@R10]\], and more efficient approaches to this mixture of racemic diastereoisomers of **1** \[[@R11]--[@R17]\], two of which were developed by our group \[[@R15]--[@R16]\].

![Structure of rosaprostol (**1**) and numbering system.](Beilstein_J_Org_Chem-12-2234-g002){#F1}

Inspired by the trend in pharmaceutical sciences and industry to replace racemic by enantiomeric drugs (so-called "chiral shift") and as part of our research program on the synthesis and study of the stereostructure--bioactivity relationship in biologically active compounds \[[@R18]--[@R19]\], including selected prostanoids \[[@R20]--[@R22]\], we decided to synthesize all four rosaprostol stereoisomers **1a--d** in enantiomerically pure form ([Fig. 2](#F2){ref-type="fig"}). The two rosaprostol stereoisomers **1c** and **1d** have an absolute configuration at C-2 of the cyclopentane ring opposite to that in natural prostaglandins of the A and J series. Therefore these compounds are expected to exhibit an increased biological stability as compared with **1a** and **1b**, and to be more efficacious in the treatment of gastric ulcers \[[@R23]\].

![The structures of stereoisomers of rosaprostol (**1**).](Beilstein_J_Org_Chem-12-2234-g003){#F2}

Recently we devised and reported the first strategy for the synthesis of the enantiomerically pure rosaprostol stereoisomers **1a--d** using the diastereoisomerically pure camphor-protected 3-\[(dimethoxyphosphoryl)methyl\]-4,5-dihydroxycyclopent-2-enones (−)-**2a** and (+)-**2b** as chiral building blocks ([Scheme 1](#C1){ref-type="fig"}) \[[@R24]\]. These compounds can be prepared from optically inactive *meso-*tartaric acid through a two-step reaction sequence. It involves a complete desymmetrization during an acid-catalyzed reaction with (+)-camphor and methyl orthoformate and the subsequent treatment of the formed methyl diester with α-phosphonate carbanion afforded diastereoisomeric ketals **2** in ca. 45% yield as a separable mixture.

![Synthesis of stereoisomeric rosaprostols **1a** and **1b** from (−)-**2a**.](Beilstein_J_Org_Chem-12-2234-g004){#C1}

According to this strategy, the starting substrate (−)-**2a** was converted into (−)-**1a** in nine steps in 18% overall yield. Then, the C-5 epimeric rosaprostol (−)-**1b** was prepared from (−)-**1a** in two steps in 72% yield ([Scheme 1](#C1){ref-type="fig"}). The remaining two stereoisomers **1c** and **1d** could be obtained from (+)-**2b**, using the same sequence of reactions. Although our first synthesis allowed us to prepare the enantiomerically pure stereoisomers of rosaprostol **1** in a straightforward way, it was not fully satisfactory from the view point of efficiency and atom and step economy. Since a detailed evaluation of the biological activity and preclinical studies requires gram quantities of each stereoisomer of **1**, we sought a shorter and more efficient approach to our targets.

Herein we disclose a new total synthesis of all enantiomerically pure rosaprostol stereoisomers **1a**--**d** in which we took advantage of our experience in the synthesis of racemic rosaprostol ((±)-**1**) \[[@R15]\]. This synthesis is the most efficient among all reported syntheses of (±)-**1** up to date \[[@R10]--[@R17]\]. As shown in [Scheme 2](#C2){ref-type="fig"}, the conversion of a simple substrate, dimethyl methanephosphonate into (±)-**1** was achieved in only seven steps and in 42% overall yield. Racemic 2-dimethoxyphosphoryl-3-hexylcyclopentan-1-one (**3**) is the key intermediate in this synthesis. This report describes the resolution of (±)-**3** into its enantiomers and their application as starting chiral reagents for the preparation of rosaprostol stereoisomers **1a**--**d**.

![Synthesis of racemic rosaprostol (±-**1**).](Beilstein_J_Org_Chem-12-2234-g005){#C2}

Results and Discussion
======================

The total synthesis of stereoisomeric rosaprostols **1a--d** commenced with the resolution of racemic 2-dimethoxyphosphoryl-3-hexylcyclopentan-1-one (**3**). Thus, a solution of (±)-**3** in methylene chloride was reacted with (+)-(*R*)-1-(1-naphthyl)ethylamine in the presence of dehydrating agents. The reaction mixture was stirred for five days at room temperature and after a usual work-up the crude mixture of diastereoisomeric condensation products (^31^P NMR assay, δ~P~ = 28.08 and 28.16 ppm) was separated into pure components by column chromatography (hexane/acetone 15:1). All the spectral data indicated that the isolated diastereoisomers **4a** and **4b** have the enamine and not imine structure that should be formed in the first reaction stage. Presumably, due to electron-withdrawing properties of the phosphoryl and carbonyl groups, the α-methine hydrogen migrates to the imine nitrogen to form the cyclopent-1-ene structure.

The pure diastereoisomers of **4** were then efficiently converted by hydrolysis under weakly acidic conditions into the corresponding enantiomerically pure cyclopentanones (+)-**3** and (−)-**3** as the desired chiral starting materials in our new stereoselective synthesis of rosaprostols **1a**--**d**. The resolution of (±)-**3** and some experimental details are depicted in [Scheme 3](#C3){ref-type="fig"}. It shows also the absolute configurations of (+)-**3** and (−)-**3** ascribed to the compounds based on their successful conversion into the known rosaprostols **1a** and **1c**, respectively.

![Resolution of racemic cyclopentanone **3**. Reagents and conditions: (a) Al~2~O~3~, SiO~2~, MS 5 Å, DCM, rt, 5 d; (b) cation exchanger Dowex 50WX4, MeOH/H~2~O 5:1, rt, 3 N HCl (drops), column chromatography.](Beilstein_J_Org_Chem-12-2234-g006){#C3}

Having successfully prepared the enantiomerically pure starting materials (+)-**3** and (−)-**3**, we could proceed with the synthesis of the four stereoisomers of rosaprostol (**1**). The synthetic pathway to stereoisomers **1a** and **1c** is outlined in [Scheme 4](#C4){ref-type="fig"}.

![Synthesis of rosaprostol stereoisomers **1a** and **1c**. Reagents and conditions: (a) KOH/Al~2~O~3~, OHC(CH~2~)~5~CO~2~Me, C~6~H~6~, 3 h rt; (b) Te, NaBH~4~, EtOH, 6 h, rt; (c) 1 N NaOH, EtOH, 3 h, 45 °C; (d) L-Selectride, THF, −75 °C, 4 h.](Beilstein_J_Org_Chem-12-2234-g007){#C4}

At first, the Horner olefination reaction of (+)-**3** and (−)-**3** with methyl 5-formylpentanecarboxylate was carried out. The use of a mixture of Al~2~O~3~ and KOH as a base in this reaction afforded the corresponding olefination products (−)-(*R*)-**5** and (+)-(*S*)-**5** in high yields. Both of them were formed as mixtures of *E* and *Z*-isomers. Although these mixtures were directly used for further transformations, for characterization purposes they were separated by column chromatography. The *E/Z* ratio in (−)-(*R*)-**5** was determined by integration of the carbonyl carbon resonances in the ^13^C NMR spectra (δ~CO~ = 209.09 and 207.79 ppm for (*Z*)-(*R*)-**5** and (*E*)-(*R*)-**5**), while in the case of (+)-(*S*)-**5** by integration of the vinylic ring carbon signals (δ~(O)CC=C~ = 139.72 and 136.18 ppm for (*Z*)-(*S*)-**5** and (*E*)-(*S*)-**5**, respectively). In the next step, the exocyclic carbon--carbon double bond was selectively reduced with sodium hydrogen telluride to give the corresponding disubstituted cyclopentanone (+)-**6** containing considerable amounts of the 1,2-*cis* isomer as revealed by ^13^C NMR spectra displaying two carbonyl carbon signals (δ = 221.2 ppm for 1,2-*trans* isomer and 220.5 ppm for 1,2-*cis* isomer). The reduction product was treated with *p*-toluenesulfonic acid in methanol for a few hours to give the desired (+)-*trans*-**6** isomer contaminated with very small amounts (4%) of the *cis*-isomer. Under the same reduction/epimerization conditions, (+)-(*S*)-**5** was successfully transformed into (−)-*trans*-**6** containing 7% of the corresponding *cis* isomer. Alkaline hydrolysis of both enantiomeric methyl esters (+)-**6** and (−)-**6** afforded the ketoacids (+)-**7** and (−)-**7**, respectively. As revealed by ^13^C NMR spectoscopy, the first of them contained only 2% of the *cis*-ketoacid **7**, while in the levorotatory ketoacid **7** the content of the *cis*-isomer was slightly higher (7%). In the final step, the ketoacid (+)-**7** was reduced stereoselectively with L-Selectride under controlled temperature conditions (−75 °C, 4 h) to give the desired stereoisomeric rosaprostol as a colorless solid (mp 41--42 °C) exhibiting an optical rotation \[α\]~D~ ^20^ = −61.0 (CHCl~3~). All physicochemical properties and spectral data confirmed that the product formed in the above reaction is identical with the stereoisomer (−)-(1*S*,2*R*,5*R*)-**1a** prepared in our earlier work \[[@R23]\].

In summary, the rosaprostol stereoisomer (−)-**1a** was synthesized from the starting cyclopentanone phosphonate (+)-**3** in four steps and 56% overall yield. As expected, the reduction of the carbonyl group in the ketoacid (−)-**7** by L-Selectride produced the second stereoisomer of rosaprostol (+)-**1c**, \[α\]~D~ ^20^ = +60.1 (CHCl~3~). The overall yield of the four-step conversion of (−)-**3** into (+)-**1c** was 54.5%.

With regard to the assignment of the absolute configuration to (+)-**3**, it is important to notice that (−)-**1a** obtained herein has the absolute configuration *R* at the C-2 stereogenic center. As the chirality at this carbon atom remains unchanged in the four-step conversion of (+)-**3** into (−)-**1a**, the same chirality has to be assigned to the corresponding carbon atom (now C-3) in (+)-**3**. Taking into account a *trans*-arrangement of the phosphoryl and *n*-hexyl substituents, the absolute configuration (2*S*,3*R*) should be ascribed to (+)-**3** according to Cahn, Ingold, and Prelog rules \[[@R25]--[@R26]\]. As a consequence, the enantiomer (−)-**3** has the absolute configuration (2*R*,3*S*).

In the course of our investigations on the synthesis of the stereoisomers **1a** and **1c** an alternative, more efficient method for the conversion of the enantiomeric methyl esters **6** into **1a** or **1c** was also elaborated as a two-reaction sequence. The first step comprises a reduction of **6** by L-Selectride at −45 °C affording the corresponding diol **8**. In the second step, a selective air oxidation of the primary hydroxy group in **8** was carried out according to the procedure described by Rhee and coworkers \[[@R27]\] to give stereoisomeric **1**. The transformation of (+)-**6** into (−)-**1a** according to the new protocol is shown in [Scheme 5](#C5){ref-type="fig"}. It is noteworthy that the overall yield of the synthesis of (−)-**1a** from (+)-**3** involving this alternative procedure was increased to 64%.

![Conversion of methyl ester (+)-**6** into rosaprostol (−)-**1a**. Reagents and conditions: (a) L-Selectride, THF, −45 °C, 3 h; (b) O~2~ (air), Pd/C, NaBH~4~, KOH, H~2~O/MeOH 2:1.](Beilstein_J_Org_Chem-12-2234-g008){#C5}

With the two rosaprostol stereoisomers **1a** and **1c** in hand, the synthesis of the remaining two stereoisomers **1b** and **1d** was readily accomplished with a Mitsunobu reaction \[[@R28]\] inverting the configuration at C-5. In fact, **1a** and **1c** were obtained through a two-step sequence starting with the methylation of (−)-**1a** and (+)-**1c** followed by a one-pot Mitsunobu esterification--hydrolysis as shown in [Scheme 6](#C6){ref-type="fig"}. In detail, treatment of rosaprostols (−)-**1a** and (+)-**1c** with diazomethane gave the corresponding rosaprostol methyl esters (−)-**9** and (+)-**9** in yields higher than 90%. Then the esters **9** were subjected to a Mitsunobu esterification under standard conditions (THF, rt) using *p*-nitrobenzoic acid (PNBA), triphenylphosphine and diisopropyl azodicarboxylate (DIAD). The *p*-nitrobenzoic acid esters (+)-**10** and (−)-**10** formed in this reaction (not shown) were immediately hydrolyzed under basic conditions affording the two desired rosaprostol stereoisomers (−)-**1b** and (+)-**1d** in 71 and 68% yield, respectively.

![Synthesis of rosaprostol stereoisomers **1b** and **1d**. Reagents and conditions: (a) CH~2~N~2~, Et~2~O, −30 °C; (b) i. PNBA, Ph~3~P, DIAD, THF, rt; ii. LiOH, EtOH, rt, 24 h.](Beilstein_J_Org_Chem-12-2234-g009){#C6}

Finally, for the sake of completeness of our total synthesis of stereoisomeric rosaprostols **1**, the *p*-nitrobenzoates (+)-**10** and (−)-**10** were isolated and fully characterized (see [Supporting Information File 1](#SD1){ref-type="supplementary-material"} for details).

Conclusion
==========

In summary, a new concise and efficient synthesis of the four enantiomerically pure stereoisomers of rosaprostol (**1**), an antiulcer drug, was accomplished. The stereoisomers (−)-**1a** and (+)-**1c** were obtained from the enantiomeric 2-phosphoryl-3-hexylcyclopentanones (+)-**3** and (−)-**3**, respectively, in four steps in about 55% overall yield. The other two stereoisomers, (−)-**1b** and (+)-**1d**, were prepared starting from (−)-**1a** and (+)-**1c** in two steps in 70% yield. The present synthesis compares favorably in terms of the required steps (halved number) and efficiency (three-fold improvement in yield) with previous reports. It uses inexpensive reagents and operationally simple reactions. Because the synthetic sequence may be performed on a multigram-scale, it is suitable for preparation of sufficient amounts of material for biological and preclinical studies.

Supporting Information
======================

###### 

Experimental procedures, spectral data and copies of the ^1^H, ^13^C and ^31^ P NMR spectra for compounds **1** and **3--10** are provided.
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